WallStreetZenWallStreetZen

NASDAQ: IRON
Disc Medicine Inc Stock Forecast, Predictions & Price Target

Analyst price target for IRON

Based on 5 analysts offering 12 month price targets for Disc Medicine Inc.
Min Forecast
$40.00+33.24%
Avg Forecast
$69.60+131.85%
Max Forecast
$85.00+183.14%

Should I buy or sell IRON stock?

Based on 5 analysts offering ratings for Disc Medicine Inc.
Buy
Strong Buy
2 analysts 40%
Buy
2 analysts 40%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IRON stock forecasts and price targets.

IRON stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-08
lockedlocked$00.00+00.00%2024-04-02
lockedlocked$00.00+00.00%2024-04-01
lockedlocked$00.00+00.00%2024-02-29
lockedlocked$00.00+00.00%2023-12-20

1 of 1

Forecast return on equity

Is IRON forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.66%

Forecast return on assets

Is IRON forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

IRON revenue forecast

What is IRON's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$18.7M
Avg 2 year Forecast
$30.9M
Avg 3 year Forecast
$158.3M

IRON vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IRON$30.02$69.60+131.85%Buy
PLRX$12.19$46.67+282.83%Buy
PRTC$26.94N/AN/A
ELVN$17.67$34.00+92.42%Strong Buy
CRGX$19.10$29.67+55.32%Strong Buy

Disc Medicine Stock Forecast FAQ

Is Disc Medicine Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: IRON) stock is to Buy IRON stock.

Out of 5 analysts, 2 (40%) are recommending IRON as a Strong Buy, 2 (40%) are recommending IRON as a Buy, 1 (20%) are recommending IRON as a Hold, 0 (0%) are recommending IRON as a Sell, and 0 (0%) are recommending IRON as a Strong Sell.

If you're new to stock investing, here's how to buy Disc Medicine stock.

What is IRON's revenue growth forecast for 2026-2028?

(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Disc Medicine's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IRON's revenue for 2026 to be $461,535,224, with the lowest IRON revenue forecast at $461,535,224, and the highest IRON revenue forecast at $461,535,224. On average, 4 Wall Street analysts forecast IRON's revenue for 2027 to be $762,199,507, with the lowest IRON revenue forecast at $88,629,572, and the highest IRON revenue forecast at $1,350,052,232.

In 2028, IRON is forecast to generate $3,906,710,560 in revenue, with the lowest revenue forecast at $3,118,768,741 and the highest revenue forecast at $5,259,280,257.

What is IRON's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: IRON) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is IRON's Price Target?

According to 5 Wall Street analysts that have issued a 1 year IRON price target, the average IRON price target is $69.60, with the highest IRON stock price forecast at $85.00 and the lowest IRON stock price forecast at $40.00.

On average, Wall Street analysts predict that Disc Medicine's share price could reach $69.60 by Apr 8, 2025. The average Disc Medicine stock price prediction forecasts a potential upside of 131.85% from the current IRON share price of $30.02.

What is IRON's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: IRON) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.